Rituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4

.

Source: Pediatric Hematology and Oncology - May 3, 2020 Category: Pediatrics Authors: Zijun Zhen Jia Zhu Juan Wang Suying Lu Feifei Sun Junting Huang Xiaofei Sun Source Type: research